Investors Newsletter

Number 3 August 10, 2014

E-QURE
ELECTRIC QUICK ULCER REMEDY

We have completed the two most important action for our listed company. Re-domicile is approves and since beginning of August we are a Delaware company. This action has great importance for future conducting of our business. We have also completed the reverse split and now the company share structure is organized and is trading for the next 20 days under the symbol ADBID. Thereafter the D will be eliminated.

We are going to file for the last stage in the process this month, which is the re-name of the company into E-QURE Corp, and hopefully will be approved during August.

We are in the process of preparing the registration statement (S1). Filing with the SEC will take place this month and we expect to become effective in the 4th quarter. At That time, ¼ of your shares will be released for trading.

We received the shares certificate for the shareholders. We will distribute it to you within a few days. Please take good care of the certificate, since it is the original. The shares are subject to Rule 144 and are restricted from trading by law for now.

We have established an Israeli subsidiary (ESQURE Medical Devices Ltd) that will conduct all the manufacturing and the marketing efforts in Europe. It will start activity during August.

We have completed the documentations with the US CRO, and intend to file to the FDA. Clinical trial will start immediately after FDA acceptance. Medical centers that will be participating have already been identified and awaiting launching the first batch of patients.

The Public company is going to enhance its Board of Directors with capable persons. The nomination will be introduced soon.

To all our investors:

You will be able to see most of our shareholders participating in this venture via our SEC filing. You can also look us up at the financial Web Sites such as OTCmarket.com, Bloomberg.com, Yahoo finance, Google finance and more.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. We are using forward-looking statements, when we discuss items in this document. These forward-looking statements and their implications are based on the current expectations of the management of E-QURE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QURE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, E-QURE undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QURE, reference is made to E-QURE's reports filed from time to time with the Securities and Exchange Commission.

E-QURE Corp. 107 Renovah Circle, Stamford, CT 06905, USA.
www.e-qure.com.
info@e-qure.com